MetabolicIn Clinical Trials

Mazdutide

Subcutaneous injection

Overview

Mazdutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist delivered as a synthetic peptide. By co-activating both receptors, it aims to combine the glucose-lowering and weight-reducing effects of GLP-1 with the energy-expenditure and hepatic fat-reducing actions of glucagon receptor stimulation.

Mechanism of Action

This dual mechanism is hypothesized to provide enhanced metabolic benefits in obesity and metabolic dysfunction-associated steatotic liver disease..

Research Summary & Key Findings

Phase 2 studies in obesity have shown significant weight reduction and improvements in liver fat content compared to placebo. Data presented at international obesity and liver meetings in 2022 and 2023 support further development in metabolic indications. Phase 3 trials are in progress to confirm these findings in larger populations.

Clinical Status

In Clinical Trials

Mazdutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection

Related Peptides in Metabolic

Find a Provider

Find a verified provider who offers Mazdutide therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Mazdutide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.